Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Optimal measuring timing of cystatin C for early detection of contrast-induced acute kidney injury: A systematic review and meta-analysis.
|
31654803 |
2020 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum cystatin C (CysC; subdistribution hazard ratio [SHR], 1.58; 1.07-2.33), episodes of previous AKI (SHR, 1.26; 1.02-1.56), and AKI stage at enrollment (no AKI [SHR, 1] vs. stage 1 [SHR, 3.28; 1.30-8.25] vs. stage 2 [SHR, 4.33; 1.76-10.66] vs. stage 3 [SHR, 4.5; 1.59-12.73]) were identified as baseline risk factors for CKD development.
|
31313333 |
2020 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma cystatin C and urine NGAL are useful for early detection of AKI.
|
31601879 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Median levels of 5 biomarkers were significantly higher in AKI cases than controls at 1-3 days before AKI onset (all µg/mmol): clusterin [58(8-411) versus 7(3-17)], beta-2-microglobulin [1632(913-3823) versus 253(61-791)], KIM1 [0.16(0.13-0.76) versus 0.07(0.05-0.15)], MCP1 [0.40(0.16-1.90) versus 0.07(0.04-0.17)], and cystatin-C [33(27-2990) versus 11(7-19)], all p<0.05; their AUROC for AKI prediction were >0.80 (confidence intervals >0.50), with average accuracy highest for clusterin (86%), followed by beta-2-microglobulin, cystatin-C, MCP1, and KIM1 (57%) after cross-validation.
|
31296157 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of thyroid function on cystatin C in detecting acute kidney injury: a prospective, observational study.
|
30727972 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
The anti-C5 antibody ameliorated the intra-renal complement activation (intra-renal C3 and C6), reduced systemic inflammation (C-reactive protein, and systemic C3), decreased intra-renal acute tubular necrosis damage and improved GFR (seen by the sensitive marker, serum cystatin C; 1.63 mg/L (I/R + placebo), 1.36 mg/L (I/R + low dose) and 1.21 mg/L (I/R + high dose), <i>p</i> = .08 and .03 compared with I/R + placebo).<b>Conclusion:</b> In I/R-induced AKI, the monoclonal anti-C5 complement factor ameliorates intra renal complement activation, decreases local and systemic inflammation and may improve GFR.
|
31662004 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded.
|
30713050 |
2019 |
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum blood urea nitrogen (BUN), creatinine (Cr) and cystatin C levels were determined in peripheral venous blood collected from 110 patients with sepsis-induced AKI and 110 healthy controls.
|
30997877 |
2019 |
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Higher serum cystatin C and urine NAG levels were independent predictors of AKI development in patients with decompensated cirrhosis.
|
30062791 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Over the past decade, numerous clinical studies have evaluated the utility of several biomarkers (e.g. neutrophil gelatinase-associated lipocalin, interleukin-18, liver-type fatty acid binding protein and kidney injury molecule-1, cystatin C) in the early diagnosis and risk stratification of AKI.
|
30179848 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention.
|
30639197 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that combining creatinine with serum cystatin C (cysC) and urinary neutrophil gelatinase-associated lipocalin (NGAL) more effectively characterizes AKI during the first 28 days of HSCT and better identifies patients at risk of adverse outcomes than creatinine alone.
|
30700793 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased urinary levels of kidney injury molecule 1 (Kim-1) as well as glycosuria were observed in colistin-treated mice, where alterations of established clinical markers of acute kidney injury (serum creatinine and albuminuria) and emerging markers such as cystatin C were inaccurate in flagging renal damage as confirmed by histology.
|
31591120 |
2019 |
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results showed a significant rise in creatinine, urea, and cystatin C (cys C) levels and upregulation of p38 mRNA, whereas a significant decline in NAD(P)H quinone oxidoreductase 1 (NQO-1) protein and downregulation of B-cell lymphoma-2 (Bcl-2) mRNA and vascular endothelial growth factor (VEGF) mRNA were recorded in AKI.
|
30976980 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased biomarker levels of acute kidney injury (AKI) in HK-2 cells, including kidney injury molecule-1, neutrophil gelatinase-associated lipocalin and cystatin C, decrease the mitochondrial membrane potential in HK-2 cells, and cause mitochondrial dysfunction, it also reduced the ratio of mitochondria-associated apoptotic protein Bax/Bcl-2, leading to cell apoptosis.
|
31599006 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
All three serum markers of AKI (cystatin C, NGAL, and IL-18) studied were positively correlated with OSA severity, and two (cystatin C and IL-18) were positively correlated with the frequency of oxygen desaturation during sleep.
|
30736871 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum cystatin C and serum or urine NGAL have been shown to predict or diagnose AKI in AP; however, this evidence come from the single center studies of low number of patients.
|
31366007 |
2019 |
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SCr, CystC and plasma NGAL were able to predict the subsequent development of AKI.
|
29369449 |
2019 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary IGFBP-7 level was predictive of severe AKI and achieved the AUC of 0.79 (P = 0.001), but was not better than serum (AUC = 0.89, P < 0.001) and urinary (AUC = 0.88, P < 0.001) CysC in predicting severe AKI.
|
29907141 |
2018 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with patients without AKI (1.01 ± 0.26 mg/L), the level of baseline serum cystatin C (CYS-C) was significantly higher in patients with AKI (3.64 ± 2.17 mg/L, <i>P</i> < 0.001).
|
30581500 |
2018 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and serum cystatin C (Cys C) are biomarkers of acute kidney injury (AKI).
|
29784944 |
2018 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary neutrophil gelatinase-associated lipocalin (NGAL) and serum cystatin C measurements for early diagnosis of acute kidney injury in children admitted to PICU.
|
29464581 |
2018 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study.
|
28941301 |
2018 |
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The measurement of serum MIOX and cystatin C levels is valuable for the diagnosis of AKI.
|
30581335 |
2018 |
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cystatin C has also been shown to outperform creatinine as an indicator of true GFR and to add information about the occurrence of acute kidney injury.
|
29775220 |
2018 |